Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CADL | 8-K | neutral | 4/10 | Candel Therapeutics reported Q2 2026 financial results with a net loss of $38.9M ($0.52/share), significantly wider than | Aug 13, 2026 |
| PULM | 8-K | neutral | 4/10 | Pulmatrix reported Q2 2026 financial results, showing a net loss of $1.036M ($0.29/share) compared to a $1.549M loss ($0 | Aug 13, 2026 |
| SBDS | 8-K | mixed | 6/10 | Solo Brands reported Q2 2026 net sales of $88.5M, down 4.1% YoY, but the net loss narrowed to $4.4M from $13.5M a year a | Aug 13, 2026 |
| ARX | 8-K | bullish | 9/10 | Accelerant Holdings announced a definitive agreement to be acquired by Thoma Bravo for $20.25 per share in cash, a 49% p | Aug 13, 2026 |
| REKR | 8-K | neutral | 5/10 | Rekor Systems reported Q2 2026 revenue of $12.7 million, up 2% YoY and 23% sequentially, with an adjusted EBITDA loss na | Aug 13, 2026 |
| VENU | 8-K | mixed | 5/10 | Venu Holding Corp reported Q2 2026 results with a slight EPS miss vs consensus but revenue growth is not directly compar | Aug 13, 2026 |
| GRCE | 8-K | neutral | 5/10 | Grace Therapeutics reported Q1 2027 results with a net loss of $15.8M ($0.91/share), significantly wider than the $3.4M | Aug 13, 2026 |
| DUKR | 8-K | mixed | 5/10 | Duke Robotics reported Q2 2026 revenue of $149,000, essentially flat YoY ($143,000), and a net loss of $726,000 ($-0.26/ | Aug 13, 2026 |
| ELMT | 8-K | mixed | 6/10 | Elmet Group reported Q2 FY2026 revenue of $66.4M (+35.2% YoY), well above the $58.1M consensus, driven by strong demand | Aug 13, 2026 |
| MGTX | 8-K | neutral | 5/10 | MeiraGTx reported Q2 2026 GAAP net income of $160.7M ($1.71 diluted EPS) vs a net loss of $38.8M ($-0.48) a year ago, dr | Aug 13, 2026 |
| SLND | 8-K | bearish | 8/10 | Southland Holdings entered into a Financial Assistance Agreement with its surety partners and a Second Amendment to its | Aug 13, 2026 |
| WNC | 8-K | neutral | 5/10 | Wabash National Corp. amended its existing credit agreement to extend the maturity of its $300 million revolving credit | Aug 13, 2026 |
| LNSR | 8-K | bullish | 7/10 | LENSAR reported a strong Q2 2026 beat, with EPS of $0.10 (diluted) crushing the consensus estimate of -$0.27, and revenu | Aug 13, 2026 |
| MH | 8-K | bullish | 6/10 | McGraw Hill reported strong fiscal Q1 2027 results exceeding expectations, with revenue of $549.9M (+2.6% YoY), GAAP EPS | Aug 13, 2026 |
| ALH | 8-K | bullish | 7/10 | Alliance Laundry reported Q2 2026 net revenue of $477M (+7% YoY) and diluted EPS of $0.34, beating the $0.34 consensus. | Aug 13, 2026 |
| PTHS | 8-K | bearish | 6/10 | Pelthos Therapeutics reported Q2 2026 revenue of $15.4M (up 45% QoQ) driven by strong Zelsuvmi prescription growth, but | Aug 13, 2026 |
| PBLS | 8-K | bullish | 7/10 | Parabilis Medicines reported Q2 2026 results, highlighting a net loss of $52.5M vs $34.8M a year ago, driven by increase | Aug 13, 2026 |
| LGN | 8-K | mixed | 6/10 | Legence Corp. reported Q2 2026 revenue of $1.26B (+110.7% YoY), beating the $1.07B consensus, but GAAP EPS of $0.17 miss | Aug 13, 2026 |
| EU | 8-K | bearish | 5/10 | enCore Energy reported a net loss per share of $0.19 for the six months ended June 30, 2026, compared to a $0.16 loss in | Aug 13, 2026 |
| CLRB | 8-K | neutral | 4/10 | Cellectar Biosciences reported Q2 2026 net loss of $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025, with R&D spend | Aug 13, 2026 |
| ADIG | 8-K | neutral | 5/10 | ADI Global Distribution Inc. reported its first quarterly results as a standalone public company following its spin-off | Aug 13, 2026 |
| INDP | 8-K | neutral | 5/10 | Indaptus Therapeutics reported Q2 2026 results with no active clinical programs, having discontinued its Decoy20 study. | Aug 13, 2026 |
| ABEO | 8-K | neutral | 5/10 | Abeona reported Q2 2026 net product revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026, driven by five patient treatmen | Aug 13, 2026 |
| FBYD | 8-K | bearish | 6/10 | Falcon's Beyond reported Q2 2026 consolidated revenue of $5.6M (more than doubled YoY from $2.5M), but generated a GAAP | Aug 13, 2026 |
| YSWY | 8-K | bearish | 6/10 | Yesway reported Q2 2026 EPS of $0.36, a 24.1% miss vs $0.47 consensus, on revenue of $843.9M (in line). Despite strong y | Aug 13, 2026 |
| CABA | 8-K | neutral | 4/10 | Cabaletta Bio reported Q2 2026 net loss of $-0.34 per share, which is in line with the consensus estimate of $-0.37 (a 8 | Aug 13, 2026 |
| CRMD | 8-K | neutral | 5/10 | CorMedix reported Q2 2026 consolidated revenue of $101.9M and net income of $26.0M ($0.33 basic EPS), compared to $39.7M | Aug 13, 2026 |
| LUNR | 8-K | mixed | 6/10 | Intuitive Machines reported Q2 2026 revenue of $206.2M, over 4x the $50.3M in Q2 2025, driven by spacecraft production a | Aug 13, 2026 |
| AFCG | 8-K | neutral | 4/10 | AFCG reported Q2 2026 GAAP net investment income of $3.5M ($0.15/share), down from $4.8M ($0.21/share) in Q1 2026. Total | Aug 13, 2026 |
| MSGS | 8-K | bullish | 7/10 | Madison Square Garden Sports Corp. reported fiscal Q4 2026 revenue of $278.7M (+37% YoY) and swung to an operating profi | Aug 13, 2026 |